Research programme: movement disorder therapeutics - PTC Therapeutics
Latest Information Update: 18 Feb 2024
At a glance
- Originator PTC Therapeutics
- Class Small molecules
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Movement disorders
Most Recent Events
- 06 Feb 2024 Early research in Movement disorders in USA (PO) prior to January 2024 (PTC Therapeutics pipeline January 2024)